Consultation on the Prescription Drug List: Lovastatin

The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will revise the listing for lovastatin on the Prescription Drug List (PDL). Only the Human part of the PDL is to be revised; the listing for Veterinary use will remain unchanged.

A question-and-answer document hhas also been created to explain some of the changes to the new Prescription Drug List and the administrative process for assigning prescription status.

How to Get Involved

This consultation is open for comment until December 4, 2014. Please read through the information provided in the link below titled “Consultation Document”. Once read, please submit your comments via email, facsimile or by mail to:

Health Canada
Prescription Drug Status Committee
Address Locator 3102C3
Holland Cross, Tower B
1600 Scott Street
Ottawa, Ontario
K1A 0K9

Telephone: 613-957-1058
Facsimile: 613-941-5035
E-mail: drug_prescription_status-statut_d'ordonnance_des_drogues@hc-sc.gc.ca

Consultation Document

Interested parties are encouraged to provide comments and suggestions by December 4, 2014.

Reporting to Canadians

The results of the consultation will be made available on this website.

If you have any questions, contact us at the Prescription Drug Status Committee.